• Welcome to Hair loss Experiences hair loss forum.

    Free impartial hair loss advice, hair transplant advice, hair loss medications and hair loss news.
    You can contact us directly at [email protected] if you experience any problems.

Histogen update May 2016

A

Admin

Member
Histogen, Inc. is a regenerative medicine company with a robust product pipeline, recurrent escalating revenues from skin care sales, and a lead therapeutic product for hair growth in clinical stage development that addresses a multibillion dollar market worldwide. The Company has raised $24M since its inception in 2007, the majority of which has been used to develop its proprietary manufacturing process, submit worldwide patents, and advance the skin care and hair growth products. To develop additional products without dilution to its shareholders, Histogen has formed three 50:50 joint ventures, the first of which is PUR Biologics. PUR is focused on the development of novel biologic products for orthopedic applications. Preclinical data has shown that its orthopedic material is anti-inflammatory and supports excellent cartilage and bone regeneration.

Initially funded by outside investors, PUR is currently supported by private label sales through a growing distributor network in the US. The Company expects to be in clinical trials in the US for both cartilage repair and bone repair in 2015. Adaptive Therapeutics was formed in July 2014 and has raised $2.5M to fund development of its lead product for late stage cancers that have extensive abdominal metastasis (pancreatic, gastric, ovarian, hepatic). Its product is non-toxic to non-cancerous cells, but has been shown to be effective in killing over 21 human cancer cell lines in research performed through collaborations with UCSD, UCSF, and Harvard University. A Phase I trial in the United States is targeted for early 2016. Histogen Aesthetics produces the CellCeuticals line of regenerative skin treatments, an advanced skincare line currently available at retailers including Nordstrom.com.

CellCeuticals is expected to be reintroduced on QVC US in Q1 2015, and to launch in certain Asian countries in 2015 through a partnership with the principals of Paul Mitchell Systems.

- See more at: https://www.zacksinvest.com/histogen-inc#sthash.ItsAXn0H.dpuf
 
Top